Trial Profile
Open-Label, Dose Increase and Phase I Study of ALT-P7 to Determine Safety, Tolerability, Pharmacokinetics for HER2 Positive Metastatic Breast Cancer Patients Who Have Progressed on Previous Trastuzumab-Based Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs ALT-P7 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Alteogen
- 14 Jan 2022 Status changed from active, no longer recruiting to completed.
- 13 Jan 2021 Planned End Date changed from 31 Oct 2020 to 30 Jun 2021.
- 13 Jan 2021 Status changed from recruiting to active, no longer recruiting.